| FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas A Picca, G Berzero, F Bielle, M Touat, J Savatovsky, M Polivka, E Trisolini, ... Neurology 90 (23), e2086-e2094, 2018 | 59 | 2018 |
| Diffuse gliomas with FGFR3‐TACC3 fusion have characteristic histopathological and molecular features F Bielle, AL Di Stefano, D Meyronet, A Picca, C Villa, M Bernier, Y Schmitt, ... Brain Pathology 28 (5), 674-683, 2018 | 52 | 2018 |
| The clinical use of IDH1 and IDH2 mutations in gliomas A Picca, G Berzero, AL Di Stefano, M Sanson Expert review of molecular diagnostics 18 (12), 1041-1051, 2018 | 49 | 2018 |
| Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions AL Di Stefano, A Picca, E Saragoussi, F Bielle, F Ducray, C Villa, M Eoli, ... Neuro-oncology 22 (11), 1614-1624, 2020 | 48 | 2020 |
| Current therapeutic approaches to diffuse grade II and III gliomas A Picca, G Berzero, M Sanson Therapeutic advances in neurological disorders 11, 1756285617752039, 2018 | 40 | 2018 |
| Longitudinally Extensive Myelitis Associated With Immune Checkpoint Inhibitors A Picca, G Berzero, K Bihan, V Jachiet, E Januel, M Coustans, C Cauquil, ... Neurology-Neuroimmunology Neuroinflammation 8 (3), 2021 | 35 | 2021 |
| Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy S Migliozzi, YT Oh, M Hasanain, L Garofano, F D’Angelo, RD Najac, ... Nature Cancer 4 (2), 181-202, 2023 | 20 | 2023 |
| Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience L Diamanti, A Picca, P Bini, M Gastaldi, E Alfonsi, A Pichiecchio, E Rota, ... Neurological Sciences 43 (3), 2031-2041, 2022 | 19 | 2022 |
| Neurological outcomes in immune checkpoint inhibitor-related neurotoxicity A Farina, C Birzu, MH Elsensohn, A Picca, S Muñiz-Castrillo, A Vogrig, ... Brain Communications, fcad169, 2023 | 17 | 2023 |
| Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors A Picca, N Valyraki, C Birzu, N Kramkimel, O Hermine, N Zahr, G Berzero, ... Neurology-Neuroimmunology Neuroinflammation 8 (6), 2021 | 16 | 2021 |
| Adult brainstem glioma: a multicentre retrospective analysis of 47 Italian patients A Rigamonti, G Simonetti, A Silvani, R Rudà, F Franchino, V Villani, ... Neurological Sciences 42, 1879-1886, 2021 | 9 | 2021 |
| Low-Coverage Whole Genome Sequencing of Cell-Free DNA From Immunosuppressed Cancer Patients Enables Tumor Fraction Determination and Reveals Relevant Copy Number Alterations A Bouzidi, K Labreche, M Baron, M Veyri, JA Denis, M Touat, M Sanson, ... Frontiers in cell and developmental biology, 1843, 2021 | 8 | 2021 |
| Peripheral neuropathies after BRAF and/or MEK inhibitor treatment: A pharmacovigilance study A Picca, C Birzu, G Berzero, P Sanchez‐Pena, L Gaboriau, F Vidil, ... British Journal of Clinical Pharmacology 88 (11), 4941-4949, 2022 | 7 | 2022 |
| Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations HJ Roberts, S Ji, A Picca, M Sanson, M Garcia, M Snuderl, U Schüller, ... Acta Neuropathologica, 1-4, 2023 | 6* | 2023 |
| Innovating Strategies and Tailored Approaches in Neuro-Oncology A Picca, D Guyon, OS Santonocito, C Baldini, A Idbaih, A Carpentier, ... Cancers 14 (5), 1124, 2022 | 6 | 2022 |
| Current and future tools for determination and monitoring of isocitrate dehydrogenase status in gliomas A Picca, AL Di Stefano, M Sanson Current opinion in neurology 31 (6), 727-732, 2018 | 6 | 2018 |
| Neurological complications of chimeric antigen receptor T cells and immune-checkpoint inhibitors: ongoing challenges in daily practice G Berzero, A Picca, D Psimaras Current Opinion in Oncology 32 (6), 603-612, 2020 | 5 | 2020 |
| Actionable targets involving FGF receptors in gliomas: Molecular specificities, spatial distribution, clinical outcome and radiological phenotype. AL Di Stefano, A Picca, E Saragoussi, G Berzero, A Alentorn, M Touat, ... Journal of Clinical Oncology 36 (15_suppl), 2005-2005, 2018 | 4 | 2018 |
| Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results A Picca, G Finocchiaro Current Opinion in Oncology 34 (6), 653-660, 2022 | 2 | 2022 |
| Basic premises: searching for new targets and strategies in diffuse gliomas G Sansone, N Vivori, C Vivori, AL Di Stefano, A Picca Clinical and Translational Imaging 10 (5), 517-534, 2022 | 2 | 2022 |
Marc SansonNeurologist, Sorbonne-UniversitéVerified email at aphp.fr
